Skip to main
NXTC
NXTC logo

Nextcure (NXTC) Stock Forecast & Price Target

Nextcure (NXTC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 64%
Buy 18%
Hold 9%
Sell 9%
Strong Sell 0%

Bulls say

NextCure Inc. is focusing on innovative immunomedicines, with promising data from its lead candidates, particularly LNCB74, which has shown superior efficacy in preclinical models for oncology applications compared to similar constructs from competitors. The advances in NC605 for chronic bone diseases and NC181 for Alzheimer's disease have also demonstrated significant efficacy in preclinical models, indicating potential for impactful treatment options. Additionally, the ongoing patient enrollment in clinical trials for NC181 signals a positive safety profile, enhancing the company's growth prospects in the biopharmaceutical landscape.

Bears say

NextCure Inc. has faced a decrease in market confidence, highlighted by the termination of Pfizer's B7-H4 ADC program, which raises concerns about the viability of NextCure's LNCB74 candidate targeting the same pathway. Furthermore, the company has reported higher-than-expected operating expenses in the fourth quarter of 2024, prompting a reduction in price targets from $4 to $3. These factors collectively contribute to a pessimistic view of NextCure's financial outlook and future growth potential.

Nextcure (NXTC) has been analyzed by 11 analysts, with a consensus rating of Buy. 64% of analysts recommend a Strong Buy, 18% recommend Buy, 9% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nextcure (NXTC) Forecast

Analysts have given Nextcure (NXTC) a Buy based on their latest research and market trends.

According to 11 analysts, Nextcure (NXTC) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nextcure (NXTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.